Recently, a meta-analysis of randomized trials evaluated 1950 patients with type 2 diabetes with and without NAFLD and concluded that SGLT-2 inhibitor treatment improved liver structure and function (49). The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.